Spruce Biosciences: Spruce Biosciences is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for rare endocrine disorders. The company’s lead product candidate, tildacerfont, is an investigational oral drug that is being evaluated in studies for the treatment of congenital adrenal hyperplasia (CAH). The company also plans to evaluate tildacerfont in other diseases impacted by elevated ACTH or adrenal androgens. Backed by investors including Omega Funds, Abingworth Bioventures, Novo Holdings, RiverVest Venture Partners, HealthCap, Rock Springs Capital, Aisling Capital, Surveyor Capital (a Citadel company) and Sands Capital, Spruce is committed to bringing new treatment options to patients with unmet needs.
Based in...
US - Pacific
Disease Space
Metabolic Disorders
1700 Montgomery Street
Suite 212
San Francisco, CA 94111
United States

Upcoming Company Event Participation

Solebury Trout Virtual Management Access Event

January 6 – January 15, 2021

Top 10 Holders of Spruce Biosciences, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Rock Springs Capital Management LP 0.96 1,019,212 0.00 Stakes 10/9/20
Citadel Advisors LLC 0.90 955,511 0.00 Stakes 10/9/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.